Novo Nordisk has initiated a €432 million upgrade to its Irish manufacturing facility to support large-scale production of oral Wegovy, a key weight-loss medication. The investment underscores growing demand for the drug and reinforces the company’s strategic push in the global obesity therapeutics market.
- €432 million capital investment in Novo Nordisk’s Irish facility for oral Wegovy production
- Target: 40% increase in oral Wegovy manufacturing capacity by 2027
- Project includes advanced production lines and sustainability upgrades
- Production ramp-up begins Q1 2027; full completion by end of 2027
- Supports Novo Nordisk’s long-term strategy in obesity therapeutics
- Directly enhances competitiveness against Pfizer (PFE) and Merck (MRK) in GLP-1 market
Novo Nordisk has commenced a major €432 million facility enhancement at its site in Ireland, specifically designed to enable commercial production of oral semaglutide, the active ingredient in Wegovy. The expansion focuses on increasing manufacturing capacity to meet rising global demand for the once-weekly oral formulation, which was recently approved for long-term weight management in adults with obesity or overweight conditions. The project marks one of the largest single investments in the company’s European infrastructure in recent years. The upgrade includes the installation of new high-throughput production lines, advanced quality control systems, and enhanced sustainability features, including energy-efficient processes and reduced water usage. These improvements are expected to support a 40% increase in oral Wegovy output capacity over the next two years. The project is scheduled for completion by late 2027, with production ramp-up beginning in the first quarter of 2027. This move comes amid strong commercial momentum for Wegovy, which generated approximately €4.1 billion in global sales during 2025. The expansion reflects Novo Nordisk’s confidence in sustained demand for its GLP-1-based therapies, particularly as obesity treatment markets continue to grow across North America, Europe, and Asia-Pacific. The investment also positions the company to better compete with rivals such as Pfizer (PFE) and Merck (MRK), which are developing their own oral formulations and combination therapies in the same therapeutic space. Market analysts note that the Irish facility upgrade strengthens Novo Nordisk’s supply chain resilience and reduces dependency on third-party manufacturers. The project is expected to create over 120 new engineering, quality, and production roles at the site, contributing to Ireland’s growing pharmaceutical industry footprint. The timing aligns with broader trends in healthcare innovation, where oral delivery systems are increasingly preferred for chronic condition management due to improved patient adherence.